IQVIA Holdings Inc. (NYSE:IQV) Receives $249.05 Consensus Price Target from Brokerages

Shares of IQVIA Holdings Inc. (NYSE:IQV) have been given an average recommendation of “Moderate Buy” by the twenty-one brokerages that are covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $249.05.

A number of equities analysts recently issued reports on the stock. Truist Financial reiterated a “buy” rating and issued a $263.00 price target (up previously from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Morgan Stanley upped their price target on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. UBS Group dropped their price target on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Stephens assumed coverage on shares of IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target on the stock. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a research note on Monday, February 10th.

IQVIA Stock Up 0.9 %

NYSE:IQV opened at $185.85 on Monday. The firm’s 50-day moving average price is $194.94 and its 200-day moving average price is $208.16. The company has a market capitalization of $32.77 billion, a PE ratio of 24.78, a P/E/G ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA has a 1-year low of $179.28 and a 1-year high of $254.54.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities analysts predict that IQVIA will post 10.84 EPS for the current fiscal year.

Institutional Investors Weigh In On IQVIA

Institutional investors have recently added to or reduced their stakes in the stock. Synergy Asset Management LLC purchased a new stake in IQVIA during the 4th quarter valued at approximately $33,000. Avior Wealth Management LLC boosted its position in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 87 shares during the last quarter. GKV Capital Management Co. Inc. bought a new position in shares of IQVIA during the 4th quarter valued at approximately $39,000. Lee Danner & Bass Inc. bought a new position in shares of IQVIA during the 4th quarter valued at approximately $44,000. Finally, Zions Bancorporation N.A. boosted its position in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 85 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.